Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy.
Lorigan, Paul C
Andrews, M C
AffiliationRockingham General Hospital, Cooloongup, Western Australia, Australia
MetadataShow full item record
AbstractRecent phase III clinical trials have established the superiority of the anti-PD-1 antibodies pembrolizumab and nivolumab over the anti-CTLA-4 antibody ipilimumab in the first-line treatment of patients with advanced melanoma. Ipilimumab will be considered for second-line treatment after the failure of anti-PD-1 therapy.
CitationEfficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy. 2016, 114 (10):1084-9 Br J Cancer
JournalBritish Journal of Cancer